AbbVie's Stock Correction: Opportunity or Warning Sign?

AbbVie [ABBV] recently traded below its 50-day moving average, marking a 4% decline over the past month despite exceeding earnings expectations in October. The stock dipped following the earnings release on Oct. 31, attributed to softness in oncology drug sales and continued underperformance in the Aesthetics segment. While a mid-November recovery pushed the stock above the 50-day SMA momentarily, renewed selling pressure has pushed it back below this key technical level. Yet the stock maintains solid footing above its 200-day SMA, suggesting short-term turbulence within a broader uptrend—a nuance that deserves investor attention.

Beyond the Technical Noise: Core Business Momentum

The real story lies beneath the surface volatility. AbbVie has engineered a remarkable transformation following Humira’s patent cliff, one of the pharmaceutical industry’s most significant challenges. Where the drug once represented over half of company revenues, AbbVie pivoted strategically by building momentum around two flagship immunology therapies: Skyrizi and Rinvoq.

These twin pillars are delivering exceptional results. Combined sales reached $18.5 billion in the first nine months of 2025, with Skyrizi annualizing near $18 billion and Rinvoq surpassing $8 billion. The company projects combined sales exceeding $25 billion in 2025 and climbing to more than $31 billion by 2027. This growth trajectory reflects not only market share gains but also successful label expansions—particularly Skyrizi’s recent indication in ulcerative colitis within the inflammatory bowel disease space.

A Diversified Growth Engine

Immunology forms the foundation, but AbbVie’s revenue diversification extends significantly. The oncology segment contributed $5.0 billion in the first nine months of 2025, up 2.7% year-over-year, with newer assets Elahere and Epkinly more than compensating for Imbruvica’s sales decline. Neuroscience emerged as a growth powerhouse, generating nearly $7.8 billion in sales, up 20.3%—driven by Botox Therapeutic, the depression medication Vraylar, and migraine treatments Ubrelvy and Qulipta.

The company’s neuroscience pipeline strengthens further with Vyalev’s international launch for Parkinson’s disease, alongside once-daily oral tavapadon currently under U.S. review. Expected approvals and clinical readouts over the next two years include pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm, lutikizumab, Temab-A, and etentamig—each positioned to extend AbbVie’s competitive moat in specialty care.

Strategic Acquisitions Fueling Long-Term Growth

AbbVie’s inorganic strategy has accelerated, completing over 30 M&A transactions since early 2024. Recent deals, including the acquisition of Gilgamesh Pharmaceuticals’ bretisilocin for major depressive disorder, demonstrate focused expansion in neuroscience and oncology while bolstering early-stage immunology assets. This disciplined M&A approach positions AbbVie for sustained innovation without overreliance on single-product performance.

Headwinds That Matter: Humira’s Decline and Aesthetics Pressure

Not everything points upward. Humira sales plummeted more than 50% in the first nine months of 2025 as biosimilar competition intensified following the 2023 U.S. launch. Payers increasingly shifted to exclusive biosimilar contracts, a trend expected to persist through 2026.

The Aesthetics division presented additional challenges, with global sales declining 7.4% as macro uncertainties dampened discretionary spending. Juvederm posted a 16.7% decline while Botox Cosmetics fell 7.4%. Management subsequently reduced 2025 Aesthetics revenue guidance from $5.1 billion to $4.9 billion, acknowledging category softness globally.

Valuation and Estimate Dynamics

AbbVie trades at 15.77x forward earnings—below the industry median of 16.59x and cheaper than peers like Eli Lilly, J&J, and AstraZeneca. The stock sits above its five-year mean of 13.45x, positioning it as reasonably valued for a diversified pharma player.

Analyst sentiment shifted modestly over the past 60 days: 2025 earnings estimates declined from $11.49 to $10.64 per share, while 2026 estimates edged slightly down from $14.42 to $14.40. These revisions primarily reflect acquisition-related costs rather than operational deterioration—a distinction worth noting for long-term investors.

Why the Correction Shouldn’t Trigger Panic Selling

AbbVie’s year-to-date gain of 26.1% substantially outpaces the industry’s 13.6% advance, delivering outperformance relative to the broader sector and S&P 500. Ex-Humira revenue growth accelerated beyond expectations in Q3, with sales rising over 20% driven by Skyrizi, Rinvoq, and neuroscience contributions.

Management guided for mid-single-digit revenue growth in 2025 with high single-digit CAGR through 2029—notable given the company faces no material patent expirations for the remainder of the decade. The 5.5% quarterly dividend increase underscores management confidence in cash generation capacity.

As long as the stock holds above its 200-day SMA, the intermediate-term bull trend remains intact. Recent trading below the 50-day average reflects profit-taking rather than fundamental deterioration. With a Zacks Rank of #3 (Hold), reasonable valuation, expected earnings growth, and a substantive development pipeline, patient investors have ample reason to maintain their positions during this tactical pullback.